TL;DR:
- MilliporeSigma, Merck KGaA’s North American Life Science division, unveils AIDDISON™ drug discovery software.
- AIDDISON™ bridges the gap between virtual molecule design and real-world manufacturability, aided by SynthiaTM retrosynthesis software API integration.
- This software employs generative AI, machine learning, and computer-aided drug design to expedite drug development.
- AIDDISON™ identifies potential compounds from over 60 billion options, possessing key drug properties such as safety, solubility, and stability.
- The platform provides guidance on the most efficient synthesis methods for these promising drugs.
- AI-driven drug discovery has the potential to save over US$70 billion by 2028 and reduce drug development time and costs by up to 70 percent.
Main AI News:
MilliporeSigma, the North American arm of Merck KGaA, Darmstadt Germany’s Life Science division, a prominent player in the realm of science and technology, has unveiled AIDDISON™, a groundbreaking drug discovery software. This innovative software-as-a-service platform marks a pivotal stride in bridging the chasm between virtual molecule design and real-world manufacturability. This remarkable achievement is made possible through the seamless integration of SynthiaTM retrosynthesis software application programming interface (API).
AIDDISON™ leverages the power of generative AI, machine learning, and computer-aided drug design to propel the drug development process into the fast lane. It draws upon a wealth of knowledge from over two decades of experimentally validated datasets from the realm of pharmaceutical R&D. The AIDDISON™ software boasts the ability to sift through an astounding 60 billion potential compounds, identifying those with the essential characteristics of a successful drug—traits such as non-toxicity, solubility, and stability within the human body. Furthermore, this platform goes beyond mere identification; it also offers strategic insights into the most efficient methods for synthesizing these drug candidates.
Karen Madden, Chief Technology Officer of Merck’s Life Science division, stated, “With millions eagerly awaiting the approval of new medications, the process of bringing a drug to market still lags, taking more than a decade and incurring costs exceeding US$2 billion on average. Our platform equips laboratories with the transformative power of generative AI to pinpoint the most promising drug-like candidates within an expansive chemical landscape. This not only expedites the journey but also ensures the most sustainable chemical synthesis route for the development of target molecules.”
The drug discovery voyage is a protracted, iterative expedition. A meager 10 percent of drug candidates that make it to Phase I evaluation ultimately succeed in reaching the market. The quest to unearth the most fitting chemical compound from a staggering universe of over 10^60 molecules demands substantial investments in terms of time, resources, and expertise. Enter the realm of Artificial Intelligence (AI) and machine learning, with AIDDISON™ software at its forefront. These cutting-edge tools unravel concealed insights hidden within vast datasets, significantly elevating the probability of delivering novel therapies to patients. It is estimated that AI has the potential to yield savings exceeding US$70 billion in the drug discovery process by 2028, potentially slashing both time and costs by up to 70 percent for pharmaceutical companies engaged in drug development.
Conclusion:
The introduction of AIDDISON™ represents a significant leap forward in the pharmaceutical market. This innovative software empowers researchers to identify viable drug candidates swiftly and efficiently, potentially revolutionizing the drug development process. With the promise of substantial cost savings and accelerated timelines, AIDDISON™ is poised to reshape the landscape of drug discovery, making it a game-changer for the pharmaceutical industry.
